Takeda Pharmaceutical Co. $TAK Shares Bought by Northwestern Mutual Wealth Management Co.

Northwestern Mutual Wealth Management Co. increased its stake in Takeda Pharmaceutical Co. (NYSE:TAK) by 7,549.2% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 259,077 shares of the company’s stock after purchasing an additional 255,690 shares during the period. Northwestern Mutual Wealth Management Co.’s holdings in Takeda Pharmaceutical were worth $4,039,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Royal Bank of Canada lifted its stake in Takeda Pharmaceutical by 11.0% during the 1st quarter. Royal Bank of Canada now owns 441,054 shares of the company’s stock valued at $6,558,000 after acquiring an additional 43,706 shares during the period. AQR Capital Management LLC lifted its stake in Takeda Pharmaceutical by 43.6% during the 1st quarter. AQR Capital Management LLC now owns 195,740 shares of the company’s stock valued at $2,911,000 after acquiring an additional 59,442 shares during the period. Goldman Sachs Group Inc. lifted its stake in Takeda Pharmaceutical by 15.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock valued at $79,120,000 after acquiring an additional 692,404 shares during the period. Focus Partners Wealth lifted its stake in Takeda Pharmaceutical by 4.1% during the 1st quarter. Focus Partners Wealth now owns 82,738 shares of the company’s stock valued at $1,230,000 after acquiring an additional 3,239 shares during the period. Finally, Sivia Capital Partners LLC acquired a new stake in Takeda Pharmaceutical during the 2nd quarter valued at approximately $351,000. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Wall Street Zen cut shares of Takeda Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 16th. Sanford C. Bernstein upgraded shares of Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a research note on Wednesday, April 8th. Zacks Research upgraded shares of Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 3rd. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Takeda Pharmaceutical in a research note on Wednesday, April 29th. Two equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy”.

Takeda Pharmaceutical Price Performance

NYSE:TAK opened at $16.22 on Monday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.27 and a quick ratio of 0.70. The firm has a market cap of $51.63 billion, a price-to-earnings ratio of 41.60 and a beta of -0.06. The company has a 50 day moving average price of $17.44 and a 200-day moving average price of $16.53. Takeda Pharmaceutical Co. has a 1-year low of $12.99 and a 1-year high of $18.90.

Takeda Pharmaceutical (NYSE:TAK) last posted its earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share for the quarter. The firm had revenue of $6.90 billion during the quarter. Takeda Pharmaceutical had a net margin of 4.31% and a return on equity of 11.07%. Equities research analysts forecast that Takeda Pharmaceutical Co. will post 1.5 EPS for the current year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.